Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Block listing Interim Review

23 Nov 2020 08:59

RNS Number : 1549G
GlaxoSmithKline PLC
23 November 2020
 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

 

Date: 23 November 2020

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline plc 2009 Deferred Annual Bonus Plan

Period of return:

From:

1 May 2020

To:

31 October 2020

Balance of unallotted securities under scheme(s) from previous return:

135,376

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

74,556

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

60,820

     

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

 

Date: 23 November 2020

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline 2009 Share Option Plan - Ordinary Shares

Period of return:

From:

1 May 2020

To:

31 October 2020

Balance of unallotted securities under scheme(s) from previous return:

254,091

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

32,278

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

221,813

     

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

 

Date: 23 November 2020

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline 2009 Share Option Plan - ADS

Period of return:

From:

1 May 2020

To:

31 October 2020

Balance of unallotted securities under scheme(s) from previous return:

4,692,680

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

64,816

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

4,627,864

     

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

 

Date: 23 November 2020

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline plc Share Save Plan 2012

Period of return:

From:

1 May 2020

To:

31 October 2020

Balance of unallotted securities under scheme(s) from previous return:

1,447,405

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

169,776

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

1,277,629

     

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRKZMZMRFRGGZG
Date   Source Headline
21st Dec 20223:30 pmRNSDirector/PDMR Shareholding
15th Dec 20223:30 pmRNSBoard and Committee Changes
13th Dec 20223:30 pmRNSDirector/PDMR Shareholding
7th Dec 20227:00 amRNSStatement: Zantac (ranitidine) litigation
5th Dec 20224:00 pmRNSTransfer of Treasury Shares
2nd Dec 20223:30 pmRNSDirector/PDMR Shareholding
2nd Dec 20227:00 amRNSEMA file accepted for momelotinib
2nd Dec 20227:00 amRNSJemperli positive trial in endometrial cancer
1st Dec 20223:00 pmRNSTotal Voting Rights
25th Nov 20224:47 pmRNSPublication of Final Terms of EMTN Notes
24th Nov 20223:00 pmRNSGSK publishes provisional 2023 dividend dates
22nd Nov 20224:00 pmRNSPublication of Supplementary EMTN Prospectus
22nd Nov 20227:00 amRNSBlenrep US Update
21st Nov 20223:30 pmRNSDirector/PDMR Shareholding
18th Nov 20224:00 pmRNSPublication of EMTN Supplementary Prospectus
15th Nov 20224:00 pmRNSBlock listing Interim Review
15th Nov 20223:53 pmRNSFinal results of outstanding Notes Tender Offer
15th Nov 20227:00 amRNSInterim results of outstanding Notes Tender Offer
11th Nov 20227:00 amRNSGSK Update: Zejula 2L in US
10th Nov 20226:10 pmRNSSanofi-GSK COVID booster vaccine approved by EU
10th Nov 20223:30 pmRNSDirector/PDMR Shareholding
10th Nov 20229:00 amRNSBlock Listing Application
8th Nov 20229:26 amRNSLaunch of Tender Offer for outstanding Notes
7th Nov 20227:00 amRNSDREAMM-3 phase III trial for Blenrep
3rd Nov 20221:00 pmRNSPublication of Suppl.Prospcts
3rd Nov 20227:00 amRNSIDMC recommends gepotidacin early efficacy stop
2nd Nov 20227:01 amRNS3rd Quarter Results
2nd Nov 20227:00 amRNSGSK RSV vaccine: US FDA Priority Review
1st Nov 20223:00 pmRNSTotal Voting Rights
28th Oct 20227:00 amRNSEMA accepts GSK RSV older adult vaccine for review
28th Oct 20227:00 amRNSEMA validates MAA for cabotegravir LA for PrEP
27th Oct 20227:05 amRNSGSK announces FDA meeting outcome on daprodustat
27th Oct 20227:00 amRNSContRAst phase III programme for otilimab update
25th Oct 202210:00 amRNSBoard Committee Changes
21st Oct 20227:00 amRNSRSV older adult vaccine submission in Japan
17th Oct 20227:00 amRNSMenveo new single-vial approve by US FDA
17th Oct 20227:00 amRNSMenveo new single-vial approved by US FDA
14th Oct 20222:11 pmRNSDirector/PDMR Shareholding
13th Oct 202212:46 pmRNSDirector/PDMR Shareholding
13th Oct 20229:44 amRNSDirector/PDMR Shareholding
13th Oct 20228:26 amRNSDirector/PDMR Shareholding
13th Oct 20227:00 amRNSEfficacy results for GSK’s older adult RSV vaccine
12th Oct 202211:42 amRNSDirector/PDMR Shareholding
10th Oct 20227:00 amRNSUS FDA approves Boostrix maternal immunisation
7th Oct 20224:38 pmRNSDirector/PDMR Shareholding
7th Oct 20224:24 pmRNSDirector/PDMR Shareholding
3rd Oct 202210:10 amRNSTotal Voting Rights
30th Sep 20225:21 pmRNSDirector/PDMR Shareholding
26th Sep 20225:09 pmRNSDirector/PDMR Shareholding
26th Sep 20227:00 amRNSGSK Chief Financial Officer succession

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.